Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Schedule of Impact of Adoption on Condensed Consolidated Statement of Operations and Comprehensive (Detail)

v3.10.0.1
Research and Development Agreements - Schedule of Impact of Adoption on Condensed Consolidated Statement of Operations and Comprehensive (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenue Recognition [Line Items]        
Total Research and Development Revenue $ 2,031 $ 648 $ 3,206 $ 2,408
Total revenue 6,752   8,601  
Net loss $ 5,244 $ 10,967 $ 23,653 $ 16,225
Net loss per share $ 0.19 $ 0.62 $ 0.87 $ 2.75
ASC 2014-09 | Effect of Adoption of ASC 606        
Revenue Recognition [Line Items]        
Total Research and Development Revenue $ 133   $ 54  
Total revenue 133   54  
Net loss $ 133   $ 54  
Net loss per share $ (0.00)   $ (0.00)  
ASC 2014-09 | Balance without Adoption of ASC 606        
Revenue Recognition [Line Items]        
Total Research and Development Revenue $ 2,164   $ 3,260  
Total revenue 6,885   8,655  
Net loss $ 5,111   $ 23,599  
Net loss per share $ 0.19   $ 0.87